Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free CALA Stock Alerts

Calithera Biosciences (CALA) Competitors

Calithera Biosciences logo
$0.0003 0.00 (0.00%)
As of 12:26 PM Eastern
Compare

CALA vs. CMRA, EVLO, CLVR, EFTR, and SMFL

Should you be buying Calithera Biosciences stock or one of its competitors? The main competitors of Calithera Biosciences include Comera Life Sciences (CMRA), Evelo Biosciences (EVLO), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), and Smart for Life (SMFL). These companies are all part of the "pharmaceutical products" industry.

How does Calithera Biosciences compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Comera Life Sciences has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of -1.06, indicating that its stock price is 206% less volatile than the S&P 500.

Comera Life Sciences has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Calithera Biosciences Neutral

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Calithera Biosciences N/A N/A N/A

Summary

Comera Life Sciences beats Calithera Biosciences on 3 of the 4 factors compared between the two stocks.

How does Calithera Biosciences compare to Evelo Biosciences?

Calithera Biosciences (NASDAQ:CALA) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Calithera Biosciences has a beta of -1.06, meaning that its share price is 206% less volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Evelo Biosciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A

0.3% of Evelo Biosciences shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Evelo Biosciences had 1 more articles in the media than Calithera Biosciences. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Calithera Biosciences. Evelo Biosciences' average media sentiment score of 0.64 beat Calithera Biosciences' score of 0.00 indicating that Evelo Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Calithera Biosciences Neutral
Evelo Biosciences Positive

Summary

Evelo Biosciences beats Calithera Biosciences on 5 of the 7 factors compared between the two stocks.

How does Calithera Biosciences compare to Clever Leaves?

Calithera Biosciences (NASDAQ:CALA) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Calithera Biosciences has a beta of -1.06, meaning that its share price is 206% less volatile than the S&P 500. Comparatively, Clever Leaves has a beta of 4212.86, meaning that its share price is 421,186% more volatile than the S&P 500.

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Clever Leaves N/A N/A N/A

Clever Leaves has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

6.9% of Clever Leaves shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by insiders. Comparatively, 8.2% of Clever Leaves shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
Clever Leaves Neutral

Summary

Clever Leaves beats Calithera Biosciences on 6 of the 6 factors compared between the two stocks.

How does Calithera Biosciences compare to eFFECTOR Therapeutics?

Calithera Biosciences (NASDAQ:CALA) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Calithera Biosciences has a beta of -1.06, suggesting that its share price is 206% less volatile than the S&P 500. Comparatively, eFFECTOR Therapeutics has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500.

In the previous week, eFFECTOR Therapeutics had 1 more articles in the media than Calithera Biosciences. MarketBeat recorded 1 mentions for eFFECTOR Therapeutics and 0 mentions for Calithera Biosciences. Calithera Biosciences' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
eFFECTOR Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Summary

eFFECTOR Therapeutics beats Calithera Biosciences on 5 of the 6 factors compared between the two stocks.

How does Calithera Biosciences compare to Smart for Life?

Calithera Biosciences (NASDAQ:CALA) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
Smart for Life Neutral

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Smart for Life N/A N/A N/A

28.4% of Smart for Life shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by insiders. Comparatively, 31.7% of Smart for Life shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Smart for Life has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Calithera Biosciences has a beta of -1.06, suggesting that its share price is 206% less volatile than the S&P 500. Comparatively, Smart for Life has a beta of 16.53, suggesting that its share price is 1,553% more volatile than the S&P 500.

Summary

Smart for Life beats Calithera Biosciences on 6 of the 6 factors compared between the two stocks.

Get Calithera Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALA vs. The Competition

Export
MetricCalithera BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1K$889.47M$6.25B$11.87B
Dividend YieldN/A4.84%2.73%5.21%
P/E Ratio0.001.7129.0428.47
Price / SalesN/A120.50476.6160.92
Price / CashN/A20.0727.6236.52
Price / BookN/A7.609.676.67
Net Income-$39.65M-$4.80M$3.55B$332.53M
7 Day PerformanceN/A-0.05%1.70%2.01%
1 Month PerformanceN/A5.50%5.62%9.19%
1 Year PerformanceN/A30.96%34.41%39.59%

Calithera Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CALA
Calithera Biosciences
N/A$0.00
flat		N/AN/A$1KN/AN/A60
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
EVLO
Evelo Biosciences
N/A$0.00
flat		N/AN/A$2KN/AN/A120
CLVR
Clever Leaves
N/A$0.00
flat		N/AN/A$1K$17.42MN/A560
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/AN/A$1KN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CALA) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...
Behind the Markets | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel